BioCentury | Aug 12, 2020

Single-asset KaNDy finds $425M exit as Bayer continues to build women’s health portfolio

...reducing hot flash frequency. Two standard menopause treatments, hormone replacement therapy and selective serotonin reuptake inhibitor Brisdelle...
BioCentury | Sep 25, 2019
Politics & Policy

Additional price cuts in nationwide expansion of China’s centralized procurement

China’s Joint Procurement Office announced steep price cuts for companies that won the tender bids for 25 drugs in the nationwide expansion of its pilot program for centralized procurement of generic and off-patent originator drugs....
BioCentury | Jun 13, 2019
Translation in Brief

Syntrix analgesic overcomes tramadol’s dependence on CYP2D6

Bypassing the metabolic conversion required for Schedule IV opiate tramadol to achieve analgesia, Syntrix has positioned desmetramadol as a safer and more effective pain therapy. Tramadol has been positioned as less likely to cause lethal...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Cell culture and mouse studies suggest inhibiting GRK2 could help treat influenza A infection. In a human alveolar basal epithelium cell line infected with human or avian strains of influenza A, an...
BioCentury | Aug 29, 2018

Sweetening the pot

...with some lasting up to 10 years. One non-hormonal therapy -- selective serotonin reuptake inhibitor Brisdelle...
BioCentury | Jun 21, 2018
Emerging Company Profile

Getting past PTSD

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms. Post-traumatic stress disorder (PTSD)...
BioCentury | Mar 29, 2017
Distillery Therapeutics


INDICATION: Heart failure In vitro and cell culture studies identified a GRK2 -inhibiting analog of Paxil paroxetine that could help treat heart failure. Structure-based design, chemical synthesis and in vitro testing of analogs of the...
BioCentury | May 30, 2016
Clinical News

MIN-117: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 84 patients with moderate to severe MDD showed that once-daily 0.5 and 2.5 mg oral MIN-117 for 6 weeks improved MADRS total score by magnitudes...
BioCentury | Apr 21, 2016
Targets & Mechanisms

Structural SERT-ainty

The publication this month of the crystal structure of the serotonin transporter unquestionably marked a technical watershed, and solved long-asked questions about why similar compounds bind the protein differently. Historically, the target revolutionized depression, spawning...
BioCentury | Feb 29, 2016
Clinical News

MIN-117: Completed Phase IIa enrollment

Minerva completed enrollment of 84 patients in a double-blind, placebo-controlled, European Phase IIa trial comparing 0.5 and 2.5 mg oral MIN-117 daily vs. 20 mg oral paroxetine daily. Minerva has exclusive, ex-Asian rights to the...
Items per page:
1 - 10 of 145